Becton, Dickinson and Company Announces Quarterly Dividend of $1.05 (NYSE:BDX)

Becton, Dickinson and Company (NYSE:BDX) announced a quarterly dividend on Tuesday, April 28th. Investors of record on Tuesday, June 9th will be paid a dividend of 1.05 per share by the medical instruments supplier on Tuesday, June 30th. This represents a c) dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, June 9th.

Becton, Dickinson and Company has increased its dividend by an average of 0.1%annually over the last three years and has raised its dividend every year for the last 53 years. Becton, Dickinson and Company has a dividend payout ratio of 28.5% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Becton, Dickinson and Company to earn $13.73 per share next year, which means the company should continue to be able to cover its $4.20 annual dividend with an expected future payout ratio of 30.6%.

Becton, Dickinson and Company Trading Down 2.0%

BDX stock traded down $2.93 on Wednesday, reaching $146.59. The company’s stock had a trading volume of 149,803 shares, compared to its average volume of 2,739,361. The business has a fifty day simple moving average of $162.11 and a two-hundred day simple moving average of $182.48. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The firm has a market cap of $41.74 billion, a PE ratio of 23.90, a PEG ratio of 10.68 and a beta of 0.29. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. The company had revenue of $4.49 billion during the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm’s revenue was up 1.6% on a year-over-year basis. During the same quarter last year, the firm posted $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, research analysts forecast that Becton, Dickinson and Company will post 12.56 EPS for the current year.

Becton, Dickinson and Company declared that its Board of Directors has approved a stock repurchase plan on Tuesday, January 27th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s management believes its stock is undervalued.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.